Price$30.58-1.40 (-4.36%)
01:45 PM07:45 PM
News · 26 weeks43-57%
2025-12-142026-06-07
Mix1390d
- SEC Filings5(38%)
- Other4(31%)
- Insider3(23%)
- Analyst1(8%)
Latest news
25 items- PRSepterna to Present Preclinical Characterization of SEP-479, an Oral PTH1R Agonist for Hypoparathyroidism, at 2026 ENDO Annual MeetingSepterna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that the first detailed preclinical characterization of SEP-479 has been accepted for an oral presentation at the 2026 Endocrine Society's Annual Meeting (ENDO 2026), taking place June 13-16, 2026, in Chicago. The presentation will highlight the pharmacologic profile of SEP-479, a potent, selective small molecule PTH1R agonist being developed for the treatment of hypoparathyroidism, including robust in vitro and in vivo activity supporting its potential as an oral therapy. SEP-479 is currently being evaluated in an ongoing Phase 1 s
- INSIDERChief People Officer Shaikhly Samira exercised 5,935 shares at a strike of $1.87 and sold $171,682 worth of shares (5,935 units at $28.93) as part of a pre-agreed trading plan (SEC Form 4)4 - Septerna, Inc. (0001984086) (Issuer)
- INSIDERChief People Officer Shaikhly Samira exercised 11,798 shares at a strike of $6.81 and sold $354,656 worth of shares (11,798 units at $30.06) as part of a pre-agreed trading plan (SEC Form 4)4 - Septerna, Inc. (0001984086) (Issuer)
- SECSEC Form 10-Q filed by Septerna Inc.10-Q - Septerna, Inc. (0001984086) (Filer)
- SECSepterna Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Septerna, Inc. (0001984086) (Filer)
- PRSepterna Highlights Business Progress and Reports First Quarter 2026 Financial ResultsCompelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026 Phase 1 Clinical Trial Initiated for SEP-479, Oral Small Molecule PTH1R Agonist for Hypoparathyroidism Cash Position of $522.1 Million Expected to Support Operating Plans at Least into 2029 SOUTH SAN FRANCISCO, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today highlighted pipeline progress and anticipated milestones and reported financial results for the first quarter ended Ma
- PRSepterna to Present at Bank of America Securities Health Care ConferenceSOUTH SAN FRANCISCO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, announced that Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna, will present at the Bank of America Securities Health Care Conference on Tuesday, May 12, 2026, at 5:00 p.m. PT in Las Vegas. A live webcast of the presentation will be available in the investors section of the company's website at www.septerna.com. The webcast will be archived for at least 30 days following the presentation. About SepternaSepterna, Inc. is a clinical-stage biotechnology compa
- ANALYSTStifel initiated coverage on Septerna with a new price targetStifel initiated coverage of Septerna with a rating of Buy and set a new price target of $43.00
- SECSEC Form DEFA14A filed by Septerna Inc.DEFA14A - Septerna, Inc. (0001984086) (Filer)
- SECSEC Form DEF 14A filed by Septerna Inc.DEF 14A - Septerna, Inc. (0001984086) (Filer)
- INSIDERSEC Form 4 filed by Bhatt Elizabeth4 - Septerna, Inc. (0001984086) (Issuer)
- SECSepterna Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Septerna, Inc. (0001984086) (Filer)
- PRSepterna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of HypoparathyroidismTrial Designed to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SEP-479 in Healthy Volunteers Data Anticipated in Late 2026 or Early 2027 SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the dosing of the first participants in its Phase 1 clinical trial of SEP-479, its potent oral small molecule PTH1R agonist being developed for the treatment of patients with hypoparathyroidism. The Phase 1 clinical trial is a single-ascending dose (SAD) and multiple-ascending dose (MAD) clinical trial
- SECSEC Form S-3ASR filed by Septerna Inc.S-3ASR - Septerna, Inc. (0001984086) (Filer)
- SECSEC Form S-8 filed by Septerna Inc.S-8 - Septerna, Inc. (0001984086) (Filer)
- SECSEC Form 10-K filed by Septerna Inc.10-K - Septerna, Inc. (0001984086) (Filer)
- SECSepterna Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Septerna, Inc. (0001984086) (Filer)
- PRSepterna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial ResultsCompelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026 Advancing SEP-479 (PTH1R Agonist) Toward Phase 1 Initiation in First Half of 2026 Cash Runway Expected to Support Operating Plans at Least into 2029 SOUTH SAN FRANCISCO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today highlighted pipeline progress and anticipated milestones and reported financial results for the fourth quarter and full year ended December 31, 2025.
- INSIDERChief People Officer Shaikhly Samira exercised 70,453 shares at a strike of $1.84 and sold $1,979,838 worth of shares (70,453 units at $28.10) (SEC Form 4)4 - Septerna, Inc. (0001984086) (Issuer)
- SECSEC Form 144 filed by Septerna Inc.144 - Septerna, Inc. (0001984086) (Subject)
- SECSepterna Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Septerna, Inc. (0001984086) (Filer)
- PRSepterna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development StrategySEP-631 Demonstrated Robust, Dose-Dependent Inhibition of Icatibant-Induced Skin Wheal Formation, with Complete Inhibition Observed at Doses as Low as 10 mg Once-Daily Well-Tolerated Across All Doses Studied with an Adverse Event Profile Comparable to Placebo; Pharmacokinetic Profile Supports Once-Daily Oral Dosing Phase 2 Development Planned to Begin with Chronic Spontaneous Urticaria in the Second Half of 2026 Company to Host Conference Call and Webcast on Monday, March 2, 2026, at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., March 01, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering oral small molecule GPCR-targeted medicines,
- PRSepterna to Present at TD Cowen 46th Annual Health Care ConferenceSOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (NASDAQ:SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, announced that Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna, will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 3:10 p.m. ET in Boston. A live webcast of the presentation will be available in the investors section of the company's website at www.septerna.com. The webcast will be archived for at least 30 days following the presentation. About SepternaSepterna, Inc. is a clinical-stage biotechnology company wit
- INSIDERPresident and COO Bhatt Elizabeth exercised 4,000 shares at a strike of $6.81 and sold $115,860 worth of shares (4,000 units at $28.97) (SEC Form 4)4 - Septerna, Inc. (0001984086) (Issuer)
- SECSEC Form 144 filed by Septerna Inc.144 - Septerna, Inc. (0001984086) (Subject)
SEPN FAQ
6 questionsWhere does SEPN stock trade?
Septerna Inc. (SEPN) is listed on NASDAQ.What sector and industry is SEPN in?
Septerna Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Septerna Inc. go public?
Septerna Inc. (SEPN) completed its IPO in 2024.What are analysts saying about SEPN?
Septerna Inc. has had 8 recent analyst actions on file. The most recent action was from Stifel: Buy with a $4300.00 price target on 2026-05-01. Recent price targets range from $1400.00 to $4300.00.What companies are similar to SEPN?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare SEPN side-by-side with any of them on Quantisnow.How can I track SEPN on Quantisnow?
Quantisnow aggregates Septerna Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SEPN to receive live email and push alerts on every new disclosure.